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PSGR promotes prostatic intraepithelial neoplasia and
prostate cancer xenograft growth through NF-κB
M Rodriguez1, W Luo1, J Weng1, L Zeng1, Z Yi2, S Siwko1 and M Liu1,2
Prostate-speciﬁc G-protein-coupled receptor (PSGR), a member of the olfactory subfamily of G-protein-coupled receptors, is
speciﬁcally expressed in human prostate tissue and overexpressed in prostate cancer (PCa). This expression pattern suggests a
possible role in PCa initiation and progression. We developed a PSGR transgenic mouse model driven by a probasin promoter and
investigated the role of PSGR in prostate malignancy. Overexpression of PSGR induced a chronic inﬂammatory response that
ultimately gave rise to premalignant mouse prostate intraepithelial neoplasia lesions in later stages of life. PSGR-overexpressing
LnCaP cells in prostate xenografts formed larger tumors compared with normal LnCaP cancer cells, suggesting a role of PSGR in the
promotion of tumor development. Furthermore, we identiﬁed nuclear factor-κB (NF-κB) or RELA as a key downstream target
activated by PSGR signaling. We also show that this regulation was mediated in part by the phosphatidylinositol-3-kinase/Akt (PI3K/
AKT) pathway, highlighting a collaborative role between PI3K/AKT and NF-κB during tumor inﬂammation downstream of PSGR in
the initial phases of prostate disease.
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INTRODUCTION
Prostate cancer (PCa) is a heterogeneous disease, with multiple
biologic processes and genetic alterations as likely underlying
causes.1 Several lines of evidence link chronic inﬂammation both
pathologically and epidemiologically2 to PCa etiology. Adminis-
tration of the heterocyclic amine PhIP (2-amino-1-methyl-6-
phenyl-imidazo[4,5–6]pyridine) induces a chronic inﬂammatory
response and results in increased hyperplasia and prostate
intraepithelial neoplasia (PIN).3 Further pathologic evidence
includes the prostatic lesion known as proliferative inﬂammatory
atrophy, a precursor to mouse PIN (mPIN), characterized by
atrophic epithelium and proliferation concomitant with an
inﬂammatory response. Thought to be the prostatic response to
repeated injury, proliferative inﬂammatory atrophy lesions are
commonly seen in association with PIN and carcinoma.4,5
Epidemiologically, diets rich in fats and meat, but low in fruits
and vegetables, have been linked to PCa incidence,6 possibly
mediated through inﬂammation owing to increased prostate
eicosanoid and prostaglandin (such as COX2) production in
response to the high fatty acid intake.2
Chronic inﬂammation may lead to cancer through diverse
mechanisms, including DNA damage resulting from increased
reactive oxygen and nitrogen species, increased cytokine-
mediated proliferation and downregulation of antitumor immune
surveillance.7–10 The constant response to injury could lead to
somatic alterations that ultimately give rise to cancer.9,11
Inﬂammation converges on several regulatory transcription
factors, including signal transducer and activator of transcription
3 (STAT3) and nuclear factor-κB (NF-κB).12–14 ΝF-κΒ is canonically
activated through phosphorylation of its regulatory IκBα kinase
complex (IKK). Activated IKK then phosphorylates the NF-κB
inhibitor IκBα, facilitating IκBα release from NF-κB and subsequent
degradation. This release from inhibition enables NF-κB nuclear
translocation and gene transcription initiation.14 G-protein-
coupled receptor (GPCR) signaling can interact with NF-κB either
to promote or inhibit an inﬂammatory response.15,16 For example,
protein kinase C zeta (PKCζ) can phosphorylate NF-κB directly at
Ser31117,18 enabling its interaction with CREB binding protein. The
scaffold protein CARMA3 links GPCRs and NF-κB by forming a
complex with BCL10 and MALT1 (the CBM complex) capable of
activating IKK as a result of G-protein alpha-q subunit
activation.19–21 The Ras homolog family member A has also been
linked to NF-κB activation, but the underlying mechanisms remain
unknown.16 Finally, oncogenes such as AKT/PKB also activate
NF-κB through the stimulation of intrinsic inﬂammatory
pathways,22 in this case, through interaction with IKK via
mammalian target of rapamycin in a phosphatase and tensin
homolog-deleted environment.23,24
PSGR, a member of the GPCR family, has a high structural
homology to the olfactory GPCR subfamily.25 Sequence analysis
shows an open reading frame of 320 amino acids and localization
to chromosome 11p15, a GPCR cluster region.26,27 Two separate
promoters drive PSGR expression.28 PSGR expression is limited to
prostate tissue with increased transcript levels in prostate tumor
samples.25,26,29,30 This overexpression was found in an average of
62% of prostate tissue/tumor samples, with the most signiﬁcant
difference being the benign tissue to PCa transition.27,31,32 This
suggests that PSGR may have a role in the initiation of a speciﬁc
subset of PCas and can be used as a potential biomarker in
early PCa.
Here, we sought to elucidate the role of PSGR in PCa. Using a
transgenic mouse model, we found that PSGR is expressed in the
apical membrane of luminal epithelial cells. PSGR overexpression
leads to an inﬂammatory reaction and increased reactive stroma
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that continues to varying degrees as mice age. Eventually PSGR
transgenic mice develop mPIN but not PCa. In an orthotopic
mouse model, PSGR overexpression in LnCaP cells promotes the
formation of larger tumors. PCR screening shows increased NF-κB
target gene expression, suggesting NF-κB regulation by PSGR.
Furthermore, we demonstrated that NF-κB activation is mediated
through the phosphatidylinositol-3-kinase//Akt (PI3K/AKT) path-
way. Our ﬁndings are the ﬁrst to reveal a functional role for PSGR
in the regulation of chronic inﬂammation and in the initiation of
prostate pathogenesis using animal models.
RESULTS
Generation of PSGR transgenic mice
We have previously reported elevation of PSGR expression in
human prostate tumors and PIN.31 To further extend these studies,
we used Oncomine (Compendia Bioscience, Ann Arbor, MI, USA)
to analyze microarray databases for PSGR expression in PCa. These
databases show that PSGR expression is increased in PCa tissues
when compared with normal prostate (Figure 1a), in accordance
with our previous ﬁndings. Next, we sought to determine whether
PSGR overexpression played a causal role in PCa initiation or
progression. We generated a mouse model that speciﬁcally
overexpressed human PSGR in the mouse prostate epithelium
by inserting the PSGR coding region under the control of an
ARR2PB promoter into the mouse genome (Figure 1b).
We conﬁrmed insertion of the transgene in two different mouse
lines by PCR of genomic DNA and expression in the prostate by
reverse transcription–PCR (Figures 1c and d). As shown in
Figure1e, overexpression of PSGR was highest in the ventral and
anterior prostate with low levels in dorsolateral prostate. PSGR
expression was localized to the apical membrane of luminal
epithelial cells. Wild-type littermates showed no increase in PSGR.
PSGR overexpression induces inﬂammation and low-grade PIN in
transgenic mice
We analyzed the PSGR transgenic mice at ﬁve different time-
points (3, 6, 9, 12 and 15 months of age) and observed distinct
morphologic changes at each age. Young (3 months) transgenic
mice showed acute prostatitis with an increase in inﬁltrating
inﬂammatory cells as well as epithelial cell shedding into the
lumen (Figure 2a). This inﬂammatory reaction eventually subsided
as the mice aged. At 9 months, however, we ﬁrst observed low-
grade mPIN lesions, with characteristic atypical cells (changed to a
columnar shape, were taller, with more abundant cytoplasm,
growing in foci of one or two layers, with hyperchromatic and
occasionally pleomorphic nuclei) as described by Shappell et al.33
and Park et al.34 in the ventral prostate. These persisted and
increased in number at later ages (12–15 months) (Figure 2b). The
PIN lesions, however, did not appear to progress to high-grade PIN
or localized adenocarcinoma. At the last two time-points, there
was a persistent inﬂammatory reaction present in the stroma with
visible thickening around the glands (Figure 2a). Proliferation
Figure 1. Generation of the PSGR transgenic mouse line. (a) Oncomine microarray data shows that PSGR is overexpressed in prostate cancer
samples compared with normal prostate tissue. (b) Diagram of human PSGR insertion into mouse genome under ARR2PB promoter control.
(c) Genotyping PCR of mouse tail DNA to screen for PSGR transgenics. (d) Reverse transcription–PCR of mouse prostates screening for PSGR
overexpression. (e) Immunohistochemical analysis of PSGR in all lobes at 12 months of age shows expression localized to apical membranes of
epithelial cells in both ventral and anterior prostate.
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Figure 2. Development of mPIN and increased inﬂammatory stromal reaction in transgenic mice. (a) Hematoxylin and eosin sections of
prostate glands from wild-type and transgenic littermates at different time intervals. Pictures show ventral lobe, magniﬁcation x100 (outer
box) and x400 (inner box). Low-power view shows an inﬂammatory reaction and shedding of cells into the lumen consistent with chronic
prostatitis, beginning at 3 months of age. This gradually progresses to LGPIN (mPIN I and mPIN II), seen at 9–12 months of age, with increased
density and cellularity of the stroma. (b) Box plot shows median±upper and lower quartiles of mPIN lesions from 10 ﬁelds per mouse, 5 mice
per genotype (*Po0.05). (c) Characterization of PSGR transgenics, including proliferation (proliferating cell nuclear antigen (PCNA)), AR and
smooth muscle actin (SMA) at 12 months of age. (d) Box plots show median±upper and lower quartiles of 10 ﬁelds per mouse, 6 mice per
genotype. PCNA, P= 0.09; AR, P= 0.01.
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markers showed increased proliferation in 12-month-old trans-
genic mice (Figures 2c and d). Also, there was a decrease in
epithelial androgen receptor (AR) (Figures 2c and d) but no
signiﬁcant differences in smooth muscle actin expression in these
mice (Figure 2c).
PSGR overexpression increases NF-κB activity
Given the evidence of chronic inﬂammation in PSGR transgenic
mice, we hypothesized that PSGR may regulate inﬂammatory
pathways that will ultimately enhance mPIN initiation and
potentially contribute to prostate cancer development in con-
junction with additional oncogenic insults. First, we analyzed our
mouse tissues for inﬂammatory gene expression using real-time
PCR. As shown in Figure 3a, there was a signiﬁcant increase in the
expression of inﬂammatory genes under the control of NF-κB,
such as inﬂammatory cytokines (interleukin-1β (IL-1β) and tumor
necrosis factor-α), proinﬂammatory interleukins (IL-23 and IL-12)
and immunosuppressant interleukins (IL-10 and IL-4). Consistent
with this, there was a signiﬁcant macrophage inﬁltration in the
gland lumens of PSGR transgenic mice as well as an increase in
the number of pNF-κB-positive cells (Figures 3c and d). Finally, we
observed NF-κB activation in older (15-month-old) transgenic
mice as indicated by elevated phosphorylation of NF-κB and its
upstream regulator the IKK complex (Figure 3b).
PSGR activates NF-κB transcription factor
To further evaluate the relationship between PSGR and NF-κB in
prostate cancer cells, we examined several human cell lines
(LnCaP, PC3, DU145, VCaP, LAPC4, MDA Pca2a and MDA Pca2b) for
PSGR expression as well as relative phosphatase and tensin
homolog levels. Only LnCaP and MDA PCa2a cells expressed PSGR
(Figure 4a). AR mRNA levels were also examined for the different
cell lines studied (Supplementary Figure S1A). We generated cells
stably overexpressing PSGR by transducing LnCaP cells with a
lentiviral vector for PSGR expression (LnCaP-PSGR cells). As shown
in Figure 4b, there was a signiﬁcant increase in PSGR expression in
cells transfected with the PSGR virus. AR mRNA levels showed no
signiﬁcant changes upon PSGR overexpression (Supplementary
Figure S1B). When PSGR was overexpressed in immortalized, non-
tumorigenic PNT1a cells, which do not normally express PSGR
(Supplementary Figure S3A),35 we noted an increase in prolifera-
tion but no change in cell migration (Supplementary Figures S3C
and D). To further conﬁrm regulation of NF-κB activity by PSGR, we
performed a luciferase assay to test for NF-κB promoter activation
Figure 3. PSGR overexpression activates inﬂammatory signaling pathways with NF-κB phosphorylation. (a) Real-time PCR analysis of ventral
prostates shows an increase in NF-κB-dependent cytokines and ILs. Data show mean± s.e.m. of three mice per genotype for three different
experiments. *P= 0.01 and **P= 0.001. (b) Western blot analysis shows increased phosphorylation of IKK1/IKK2 accompanied by the activation
of NF-κB in transgenic mice. (c) Immunohistochemistry shows increased inﬁltration of macrophages (Mac) (P-value= 0.001) as well as
an increased number of cells with active NF-κB in their nuclei (S536) (P-value= 0.04). (d) Box plots show median±upper and lower quartiles of
10 ﬁelds per mouse, 5 mice per genotype.
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Figure 4. PSGR overexpression activates NF-κB. (a) PSGR and phosphatase and tensin homolog (PTEN) expression in prostate cancer cell lines
by RT and quantitative PCR (qPCR). Bar graph shows qPCR of PTEN expression levels as mean± s.e.m. of three mice per genotype. (b) Relative
PSGR gene expression of LnCAP-overexpressing cells. Data are shown as fold change relative to control. (c) Luciferase assay in HEK293 cells
shows signiﬁcant activation of NF-κB with PSGR overexpression. White bar indicates HEK293-Ctrl cells; black bars indicate HEK293-PSGR cells.
(d) NF-κB activity is dose-dependent on increasing concentration of PSGR plasmid DNA transfected into HEK293 cells. (e) Western blot shows
NF-κB activation upon 10% FBS stimulation in LnCAP cells. (f) Activation of NF-κB in LnCAP-PSGR-overexpressing cells induces expression of
several NF-κB target genes including cytokines and cytokine receptors (*P-value o0.0002). (g) Serum stimulation in PSGR-overexpressing cells
induces nuclear localization of NF-κB.
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upon serum stimulation. Human embryonic kidney 293 (HEK293)
cells lack endogenous PSGR expression (data not shown), and
exhibit minimal NF-κB promoter activity. Upon exogenous PSGR
expression, we observed a signiﬁcant activation of NF-κB in
HEK293 cells (Figure 4c). NF-κB activity increased with increasing
PSGR expression up to a saturation point for this activity
(Figure 4d). Also, NF-κB phosphorylation (S536) was increased
upon 10% fetal bovine serum (FBS) stimulation in LnCaP− PSGR
cells (Figure 4e), conﬁrming NF-κB pathway activation. Next, we
examined the RNA levels of different inﬂammatory pathway
genes. We conﬁrmed upregulation of cytokines, including CCL2,
CCL5 and COX2, but saw no production of ILs, including IL-1b, IL-2
and IL-6 (Figure 4f). Finally, in response to serum stimulation, we
observed nuclear translocation of NF-κB in PSGR-expressing LnCaP
cells (Figure 4g), further supporting NF-κB activation downstream
of PSGR.
PSGR enhances oncogenesis in prostate tissue
To test PSGR function in tumor progression, we injected stable
LnCaP-PSGR cells directly into the prostates of nu/nu mice and
analyzed orthotopic prostate xenografts 1 month after surgery
(n= 7 mice per group). Although we did not observe a statistically
signiﬁcant increase in orthotopic tumor incidence in LnCaP-PSGR
cells (control: 3/7 (42% incidence); PSGR: 5/7 (72% incidence)),
supporting our transgenic mouse data suggesting that PSGR alone
is not an oncogene, there was a ﬁvefold increase in tumor prostate
mass upon PSGR overexpression (control 1.05 g (95% conﬁdence
interval: 0.296–1.817) and PSGR 5.34 g (95% conﬁdence interval:
1.633–9.052) (P= 0.023)) (Figures 5a–c). This supports a role for
PSGR in promoting prostate tumor progression, and argues
against the PSGR elevation observed in human prostate cancers
being merely a bystander effect. Histologic analysis of these
tissues showed altered morphologies, including small tumorigenic
foci, in all injected prostates of both groups, but only LnCaP-PSGR-
injected mice showed predominant adenocarcinoma in all
prostatic lumens (Figure 5d). LnCaP-PSGR-injected prostate
showed increased proliferation in both the stromal and epithelial
compartments (Figure 5e). These mice also had increased
inﬂammatory cell inﬁltration (Figure 5f) compared with controls,
in accord with the data from PSGR transgenic mice (Figure 3c), as
well as increased AR expression in the stroma (Figure 5g).
PSGR activates NFκB through the AKT pathway
LnCaP-PSGR cells activated both AKT and NF-κB upon 10% FBS
stimulation (Figure 6a). Transgenic mice also showed activation of
AKT (Figure 6b). To test whether AKT mediates PSGR regulation of
NF-κB, we stimulated LnCaP cells (LnCaP-Ctrl and LnCaP-PSGR)
with 10% FBS for 20 min in the presence or absence of speciﬁc
pathway inhibitors including MK-2206 (AKT), H-89 ( protein kinase
A (PKA)), GF109203X (PKC), C3 (Ras homolog family member A)
and SB203580 (p38), and tested for NF-κB activation. We found
downregulation of NF-κB activity with AKT inhibitor (MK-2206)
treatment (Po0.05) (Figure 6c). Other GPCR canonical pathways,
including the PKA-cAMP-CREB pathway and the PLC-PKC-Ca2+
pathway, were also analyzed for NF-κB activity. The former
showed increased NF-κB phosphorylation upon PKA inhibition,
while the latter showed a mild decrease in NF-κB phosphorylation
in the presence of PSGR (Figure 6d). We tested the functional
relationship of PSGR, AKT and NF-κB using two approaches. First,
through quantitative PCR, we measured NF-κB-dependent gene
expression upon pathway inhibition and observed a decrease in
NF-κB target gene (CCL2, CCL5, CXCR4 and Vimentin) expression
with AKT inhibition, only in PSGR-overexpressing cells (Figure 6e).
Second, we stimulated our cells with 10% FBS with or without AKT
inhibitor and observed NF-κB intracellular localization. Addition of
the inhibitor abrogated NF-κB nuclear translocation in LnCaP-
PSGR cells (Figure 6f), suggesting that PSGR induces an
inﬂammatory reaction through PI3K/AKT-mediated NF-κB activa-
tion in the prostate.
DISCUSSION
The expression pattern observed for PSGR, which is highly speciﬁc
to human prostate and signiﬁcantly increased in PCa,31 raised the
question whether PSGR has an important role in the initiation of
this disease. We hypothesized that indeed, owing to its changes in
expression, PSGR possesses oncogenic properties that aid in the
development of prostate cancer. PSGR overexpression induced a
prostatitis reaction relatively early in life (3 m), with inﬂammatory
cell inﬁltration persisting beyond this time point. At 9 months of
age, transgenic mice developed mPIN and an increased reactive
stroma. However, even beyond 12 months of age, the prostatic
lesions in these mice did not progress to adenocarcinoma,
suggesting that PSGR can alter the prostate microenvironment
toward an inﬂammatory phenotype and induce initial prostatic
lesions, and also that further genetic mutations may be needed to
produce prostate cancer. Chronic inﬂammation is one of several
biologic processes thought to have a key role in prostate cancer
initiation.1 It can increase proliferative signals of both epithelial
and stromal cells, and also create an oxidative stress-prone
environment that could easily facilitate the appearance of new
genomic alterations, including mutations that drive further disease
progression.36 Using prostate xenografts, we demonstrated a
strong inﬂammatory and tumor-promoting effect of PSGR over-
expression in human cancer cells. PSGR-overexpressing cells
produced a larger tumor burden and had increased stromal
proliferation. Inﬂammatory cell inﬁltration was also much higher in
PSGR-overexpressing tumors when compared with controls,
similar to what was seen in PSGR transgenic mouse models.
Expression of AR was increased in stromal cells of PSGR-
overexpressing tumors compared with controls, suggesting a
possible relationship between PSGR and AR. Analysis of several
prostate cancer cell lines showed different levels of mRNA
expression for AR, but overexpression of PSGR had no direct
effect on AR mRNA levels, suggesting an indirect or posttransla-
tional relationship between these proteins. While the nature of the
interaction between the AR with PSGR in prostate cancer remains
a crucial unresolved question, taken together, these data suggest
that PSGR can function to promote tumor formation and that it
may use modulation of inﬂammatory pathways in conjunction
with AR to cause this effect.
The transcription factor NF-κB is central to inﬂammation. NF-κB
signaling has been linked to prostate cancer cell survival and
disease progression to hormone independence.37 Its activity is
reported to be higher in androgen-independent cell lines as well
as in metastatic disease, and it correlates with poor prognosis,37,38
but little has been studied on the role of NF-κB in initial phases of
prostate disease. We were able to conﬁrm the regulatory
relationship between PSGR and NF-κB in the prostate by showing
PSGR-dependent NF-κB activity and phosphorylation upon serum
stimulation. We observed increased expression of NF-κB-depen-
dent cytokines such as CCL2, CCL5 and the cytokine receptor
CXCR4 in epithelial LnCAP-PSGR-overexpressing cells, but saw no
signiﬁcant changes in IL levels. However, we did ﬁnd signiﬁcantly
increased levels of ILs when we analyzed the prostate tumor
samples from mice. This suggests that the lack of ILs in the
epithelial cells could be because it is not the epithelium but the
inﬁltrating inﬂammatory cells that ultimately produce these
mediators of inﬂammation. We also showed nuclear localization
of NF-κB upon 10% FBS stimulation in the presence of PSGR, and
that the presence of PSGR, with or without 10% FBS, induced p65
phosphorylation (S536). Protein levels do not directly correlate
with pAKT (S473), but we found increased pAKT levels in
transgenic mice at 12 months of age, suggesting it may have a
potential role in PSGR-induced mPIN. When AKT is blocked with
PSGR in prostate cancer
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Figure 5. PSGR enhances oncogenesis in prostate tissue. (a) Prostate orthotopic cell implantation shows PSGR-overexpressing cells produce
larger tumors than controls. (b) Urinary system weights are in accordance with tumor progression (*P= 0.023). Data of n= 7 per group.
(c) Representative images of tumor sizes in xenografts injected with LnCAP-Ctrl vs LnCAP-PSGR cells. (d) Morphologic differences between
xenograft tissues show tumor formation in the presence of PSGR (n= 7 per group). Data show representative median box plots±upper and
lower quartiles (P-value= 0.001). (e) PSGR xenografts show increased proliferation compared with Ctrl prostates (n= 7 per group). Data show
representative median box plots±upper and lower quartiles (P-value o0.0001). (f) Immunohistochemistry of xenograft tissue for T cells (CD3)
and macrophages (Mac) shows elevated T-cell inﬁltration in PSGR-overexpressing xenografts (n= 7, Po0.05). (g) Immunohistochemistry of
xenograft tissue for AR shows increased stromal AR expression in PSGR-overexpressing xenografts (n= 7, Po0.05).
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an AKT-selective inhibitor, MK-2206, p65 (S536) further decreased
in the presence of PSGR. Inhibition of AKT also functionally
blocked NF-κB-dependent cytokine production and nuclear
localization in our PSGR-overexpressing cell lines as well. We
analyzed other canonical GPCR pathways for NFκB activation and
found that inhibition of the PKA-cAMP pathway increased NF-κB
PSGR in prostate cancer
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phosphorylation, in accordance with published results.16 High
concentrations of GF109203X (6 μM), sufﬁcient to inhibit all PKC
isoforms, showed a modest decrease in NF-κB phosphorylation. A
possible link between PKC and AKT cannot be ruled out with our
data. Nonetheless, PKC inhibition does not affect AKT phosphor-
ylation levels nor does AKT inhibition affect PKC phosphorylation
(Supplementary Figure S2B), suggesting that this could represent
an alternate pathway directly between PKC and NF-κB.18 However,
we cannot rule out nonspeciﬁc effects of GF109203X on AKT at
this concentration or the possibility of biased PSGR ligands in the
serum capable of activating NF-κB through PKC. Further experi-
ments are needed to elucidate the exact role of PKC downstream
of PSGR.
AKT can activate NF-κB in the presence of androgens to induce
normal prostate epithelial cell proliferation.39 Overexpression of
PSGR can thus cause prolonged NF-κB activation through AKT,
leading to chronic inﬂammation and increased cell proliferation,
linking two important survival pathways to initial disease.
Importantly, PSGR overexpression modulates these pathways to
change the prostate microenvironment before disease onset.
PSGR overexpression was also clinically correlated to higher non-
organ-conﬁned (pT3) disease and higher PSA levels,32 suggesting
that it may have a further role in prostate cancer progression, with
possible links to the AR. Our work for the ﬁrst time uses mouse
models to demonstrate NF-κB linkage to premalignant prostate
lesions as a direct result of GPCR activation. We found no
activation of NF-κB in the presence of PSGR by stimulating the
receptor with β-ionone (data not shown), its currently described
agonist.40 This is in agreement with the hypothesis that GPCRs
can bind to multiple ligands, which have different potentials for
activating downstream signaling pathways.15 It would be of
signiﬁcant interest to identify the ligand(s) that can activate NF-κB
through PSGR, which would represent an attractive new
therapeutic target both for initial and potentially more advanced
stages of prostate cancer.
MATERIALS AND METHODS
Generation of PSGR transgenic mice
All experiments involving animals were conducted according to a protocol
approved by the Texas A&M Health Science Center institutional animal
care and use committee. The human PSGR cDNA was cloned into the
pBSK-SSI plasmid under the control of a rat ARR2PB promoter with a poly A
site and a chicken insulator sequence. The transgenic fragment was
excised by digestion with BssHII enzyme and an 8.5 kb fragment was used
for pronuclear microinjection into FVB/N mice. Genomic DNA was puriﬁed
from the tails of founder mice (F1) at day 14 after birth and screened
with human PSGR-speciﬁc primers: PSGR-ClonF (5′-ATGGTGGATCCCAATGG
CAA-3′) and PSGR-ClonR (5′-CTAGGGCTCTGAAGCGTGTG-3′). To test for
PSGR expression, total RNA was isolated from the prostate, reverse
transcribed and ampliﬁed with PSGR-speciﬁc primers. Screening was
performed through genomic DNA extraction from tail tissue digested
with proteinase K (20 mg/ml) overnight and then heat-inactivated. PSGR
genotyping primers include: PSGR-F (5′-CCGATATCGCCACCACCATGAG
TTCCTGC-3′); PSGR-R (5′-CCGATATCGGGTCACTTGCCTCCCAC-3′). Animals
were inbred for three generations (F3) and only littermates were used for
experimental comparisons.
Reverse transcription–PCR and real-time PCR
RNA was extracted using TRIzol (Ambion-LifeTechnologies, Grand Island,
NY, USA). A total of 3 μg RNA was used for cDNA, together with a PSGR-
speciﬁc primer sequence (5′-TGAGTCTCAGCTTGACTGAGC-3′) and oligo(dT)
primers (Promega, Madison, WI, USA). PSGR expression was later detected
using real-time PCR primers: rt-OR51E2-F1 (5′-TTCCTGCAACTTCACAC
ATGCCAC-3′) and rt-OR51E2-R1 (5′-TGGATGTGGATAAGGCCAGGTCAA-3′).
Other real-time PCR primers used are included in the Supplementary Data.
Inhibitors used included: H-89 (1 μM) (Enzo Life Sciences, Farmingdale, NY,
USA), GF109203X (6 μM) (Tocris Biosciences, Bristol, UK), MK-2206 (1 μM)
(Selleck, Houston, TX, USA), C3 (0.5 mg/ml), Y27632 (Selleck) and SB239063
(1 μM) (Calbiochem, Millipore, Billerica, MA, USA). All inhibitors were used as
per the manufacturer’s recommended concentrations.
Histology
Prostate tissue was dissected together with the genitourinary system and
separated by lobes under the microscope. Tissues were ﬁxed in zinc
formalin (Richard-Allan Scientiﬁc, Kalamazoo, MI, USA) for 7 h and
transferred to 70% ethanol for 48 h. Next, samples were dehydrated
through graded alcohols, parafﬁn embedded and cut into 5 μM sections.
Morphologic analysis was performed after hematoxylin/eosin staining. For
immunohistochemistry, slides were baked at 65 °C for 3 h and rehydrated
in graded alcohols (100%, 95%, 85%, 70% and water), and then boiled for
30min in preheated 10mM sodium citrate. Vectastain ABC Kit (Vector
Laboratories Inc., Burlingame, CA, USA) was used to stain samples,
according to the manufacturer’s instructions. Antibodies used included:
PSGR (1:1000; ab13383; Abcam, Cambridge, MA, USA), AR (1:200; N-20;
Santa Cruz Biotechnologies, Santa Cruz, CA, USA), CK5 (1:1000; ab53121;
Abcam), CK8 (no dilution required; rdi-pro61038; Fitzgerald, Acton, MA,
USA), α-smooth muscle actin (1:1000; A2547; Sigma, St Louis, MO, USA), NF-
κB-p65 (S276, 1:100; no. 4764; Cell Signaling Technologies (CST), Danvers,
MA, USA), Ki67 (1:500; NB110-89719; Novus Biochemicals, Littleton, CO,
USA), macrophage (1:200; ab22506; Abcam). Photomicrographs were taken
using a Nikon Eclipse 80i microscope (Nikon, Tochigi, Japan) and
acquired using NIS-Elements BR 3.2. For immunocytochemistry, cells were
seeded on sterilized Histobond Microscope Slides (VWR, Radnor, PA, USA)
and ﬁxed with zinc formalin for 15min. Cells were then permeabilized
with phosphate-buffered saline containing 0.25% Triton X-100 for
10min and blocked in 1% bovine serum albumin for 1 h. Cells were
left in primary antibody overnight at 4 °C. The next day, cells were washed
and incubated in secondary antibody, washed, stained in To-Pro3
(Invitrogen, Carlsbad, CA, USA) for 10min and mounted. Antibodies used
include NF-κB-p65 (1:100; no. 4764; (CST)). Immunocytochemical photo-
micrographs were taken using a Zeiss Axiovert 200M microscope with
Zeiss EC Plan NeoFluar lenses equipped with a Zeiss LSM 510 camera and
using the manufacturer’s LSM 510 image acquisition software program
(Zeiss, Jena, Germany).
Immunoblotting
Protein was extracted from tissue and cell samples using RIPA buffer
supplemented with proteinase inhibitors (1:1000) aprotinin, leupeptin,
pepstatin A, PMSF, EDTA, EGTA, Na ﬂuoride and Na orthovanadate (Sigma).
Samples were then diluted in 5× sodium dodecyl sulfate buffer and boiled
for 5min. Fifty micrograms of protein was used per sample. Antibodies used
include β-actin (1:1000; Santa Cruz Biotechnologies), IkBα (1:1000; no. 4814;
CST), phospho-IKK (S176/180) (1:1000; no. 2697; CST), phospho-p65 (S536)
(1:1000; no. 3033; CST), p65 (1:1000; no. 4764; CST), phospho-PKCζ (1:1000;
no. 9378; CST), PKCζ (1:1000; no. 9368; CST), phospho-CREB (1:1000; no.
9198; CST), CREB (1:1000; no. sc-186; Santa Cruz Biotechnologies), phospho-
AKT (S473) (1:1000, no. 4060; CST), phospho-AKT (T308) (1:1000; no. 9275;
CST), pan-AKT (1:1000; no. 4691; CST). Western blots were quantiﬁed using
ImageJ software (http://imagej.nih.gov/ij/), according to the software’s
instructions. Total protein levels were used as normalization controls.
Figure 6. PSGR regulates NF-κB activity through the PI3K/AKT pathway. (a) NF-κB and AKT are phosphorylated upon 10% FBS stimulation of
LnCaP (Ctrl) and LnCaP-PSGR (PSGR) cells. (b) Prostates from transgenic mice show increased AKT phosphorylation at 15 months of age.
(c) Treatment of cells with AKT inhibitor MK-2206 decreases NF-κB phosphorylation in the presence of PSGR. (d) Treatment of cells with PKC
inhibitor (GF109203X) slightly decreased NF-κB phosphorylation, whereas PKA inhibitor (H-89) treatment increased NF-κB phosphorylation.
(e) AKT inhibition (MK-2206) blocks transcription of NF-κB-dependent target genes, including cytokines CCL2 and CCL5, as well as the EMT
marker Vimentin (VIM). PI3K inhibition (LY294002) does not show the same effect. Data show mean± s.e.m. of three repeats per experiment
for three different experiments. White bars denote LnCAP-Ctrl cells and black bars show LnCAP-PSGR cells. (f) Nuclear localization of NF-κB is
blocked upon AKT inhibition.
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Lentivirus cell lines
The 293FT, HEK293 and LnCaP cell lines were purchased from ATCC
(Manassas, VA, USA) and passaged for fewer than 6 months. PNT1A cells
were a gift from Dr Fen Wang (Texas A&M Health Science Center,
Houston, TX, USA). All stable cells were kept in RMPI-1640 growth media
(Hyclone, Logan, UT, USA) with 10% FBS (Atlanta Biologicals, Lawrenceville,
GA, USA). For overexpression, hPSGR was cloned into the pLVX lentivirus
plasmid (Clontech Laboratories, Mountain View, CA, USA) and transfected
together with packaging plasmids pMD2.G (Addgene, Cambridge, MA,
USA) and psPAX2 (Addgene) using calcium phosphate (Clontech CalPhos
Transfection Kit, Clontech Laboratories) into 293FT cells (Invitrogen).
Cloning primers included: PSGR-ClonF (5′-TGCGAATTCATGAGTTCC
TGCAACTTVAC-3′) and PSGR-R (5′-TATTCTAGATCACTTGCCTCCCACAG
CCTG-3′). Infection efﬁciency was measured under ﬂuorescence micro-
scopy for the presence of green ﬂuorescent protein-positive cells. Cell
media were then harvested, supplemented with Polybrene (Millipore) and
used to infect LnCaP cells directly.
Luciferase assays
PSGR was cloned into pcDNA3.1 expression plasmid (Invitrogen) using
speciﬁc primers (pcDNAPSGR-F: 5′-TTTTCTAGAGTCGACAGTGTGACCTCACC
CTCTCCAGTC-3′; pcDNA-PSGR-R: 5′-TGGAAGCTTAAGGGTCACTTGCCTCCC
ACAG-3′); the RTPS1 plasmid (for membrane localization) was a gift
from Dr H Matsunami (Duke University, Durham, NC, USA), and NF-κB-Luc
(SA Biosciences, Qiagen, Valencia, CA, USA) and pGL3-Basic (Promega)
were purchased. HEK293 cells were cultured in Dulbecco's modiﬁed
Eagle's medium (Hyclone) with 10% FBS. They were seeded
(5000 cells per well) in 24-well plates and transfected with 0.8 μg DNA
(pcDNA/PSGR, RTPS1 and luciferase plasmid) with Lipofectamine 2000
for 7 h and left incubating for 48 h. Afterwards, cells were serum starved
for 3 h in Dulbecco's modiﬁed Eagle's medium with 0.5% FBS and
subsequently stimulated with 10% FBS as described for speciﬁc
experiments.
Xenograft assays
PSGR-overexpressing LnCaP cells were prepared at 100 000 cells per 100 μl
in a mixture of RPMI-1640 (Hyclone) with 10% FBS (Atlanta Biologicals)
(50%) and growth factor-enriched Matrigel (50%) (BD Biosciences, San
Jose, CA, USA). Nu/nu mice (Charles River Labs, Wilmington, MA, USA) were
anesthetized, and an incision was made in the abdominal skin and
musculature to expose the genitourinary tract. Cells (100 μl per mouse)
were injected directly into a single site of the ventral prostate. Mice were
observed for prostate cancer progression for a month after surgery. Mice
were then killed and tissues processed for histologic examination.
Statistical analysis
Data analysis is shown as mean with standard error. Statistical differences
between groups were compared using two-tailed Student's t-test. P-values
and conﬁdence intervals were obtained using the R statistical software
package (R Foundation, Vienna, Austria).
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